Targeted nanoparticles incorporating siRNA offer promise for cancer treatment

May 20, 2007

The use of targeted nanoparticles offers promising techniques for cancer treatment. Researchers in the laboratory of Mark E. Davis at the California Institute of Technology have been using small interfering RNA (siRNA), sometimes known as silencing RNA, to "silence" specific genes that are implicated in certain malignancies.

One of the primary challenges associated with this type of therapy is delivering the therapeutic agent into the body and then to the tumor in a safe and effective manner. By using targeted nanoparticles, researchers have demonstrated that systemically delivered siRNA can slow the growth of tumors in mice without eliciting the toxicities often associated with cancer therapies. The results of this research are being presented this week at the NSTI Nanotech 2007 Conference in Santa Clara, CA.

The Caltech researchers have incorporated siRNA into nanoparticles that are formed completely by self-assembly, characterized the behavior of these nanoparticles and studied their safety and efficacy in mice.

Using extensive physicochemical and biological characterization, the investigators are able to estimate the composition of individual nanoparticles and to correlate the nanoparticle structure with its biological function. This quantitative approach provides unique insights into the design of more effective nanoparticle carriers.

According to the lead author of the study, Derek W. Bartlett, "Safe and effective delivery remains perhaps the greatest impediment to the clinical realization of small interfering RNA (siRNA) in cancer therapy. Formation of siRNA nanoparticles using cyclodextrin-containing polycations is one of the most promising strategies for systemic siRNA delivery, and such nanoparticles are expected to enter Phase I clinical trials by late 2007. Our most recent work examines the impact of various dosing schedules and surface modifications on the efficacy of these siRNA nanoparticles in preclinical cancer models. By combining the experimental data with a mathematical model of siRNA-mediated gene silencing, we illustrate several practical considerations that we believe will be directly relevant to the clinical application of siRNA-based therapeutics in cancer therapy."

Source: Elsevier Health Sciences

Explore further: New electronic stent could provide feedback and therapy—then dissolve

Related Stories

Domino's taking orders via tweet

2 hours ago

Domino's on Wednesday launched perhaps the easiest way to satisfy a pizza craving this side of mind reading: order by tweet.

Recommended for you

Self-replicating nanostructures made from DNA

4 hours ago

(Phys.org)—Is it possible to engineer self-replicating nanomaterials? It could be if we borrow nature's building blocks. DNA is a self-replicating molecule where its component parts, nucleotides, have specific ...

Non-aqueous solvent supports DNA nanotechnology

May 27, 2015

Scientists around the world are using the programmability of DNA to assemble complex nanometer-scale structures. Until now, however, production of these artificial structures has been limited to water-based ...

Nanosilver and the future of antibiotics

May 27, 2015

Precious metals like silver and gold have biomedical properties that have been used for centuries, but how do these materials effectively combat the likes of cancer and bacteria without contaminating the ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.